18th December 2008

Vodafone Ventures Ltd, the corporate venture capital arm of Vodafone Group, has made an undisclosed investment in t+ Medical, a provider of mobile phone based technology used to transfer patient biometric data.

The technology is currently used for the management of long-term health conditions and helps thousands of people in the UK manage their conditions each year.

The additional funding from Vodafone Ventures will accelerate the roll-out of mPRO (mobile patient reported outcomes) platform which has been specially designed for use in clinical trials.

The mPRO platform offers a number of clear benefits:

• speed new drugs to market by reducing the all important timelines between drug discovery and launch

• help increase patient safety by eliminating the inaccuracies caused by subjects not completing their paper diaries

• help pharmaceutical companies move towards a technological system of patient data capture as recommended by the FDA

• real-time analysis of clinical data enabling early adaptations to trials

• familiar mobile phone hardware delivers high levels of compliance among users

The technology enables the easy collection of patient data in clinical trials via a mobile device. Data is entered by subjects into an interactive diary programme on their mobile. Using secure mobile networks, the information is automatically and instantly downloaded to servers where it can be analysed, ensuring any significance in the results is identified at the earliest possible opportunity.

Peters Suh, President of Vodafone Ventures said: “This investment will help to ensure that t+ Medical is able to deliver on its potential while bringing greater scale to the mHealth market.”

Use to send this story to a colleague or to add it to your social web.

Subscribe to the Wireless Healthcare free weekly newsletter

Disclaimer